Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Not yet recruiting 2Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Hepatocellular 9Squamous Cell Carcinoma of Head and Neck 4Nasopharyngeal Carcinoma 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Pancreatic Neoplasms 2Locally Advanced Rectal Cancer 2Colonic Neoplasms 2Cervical Cancer Metastatic 2Breast Neoplasms 2Adenocarcinoma 2Turcot syndrome 1Salivary Gland Neoplasms 1Recurrence 1Rectal Cancer Patients 1Non-squamous Non-small-cell Lung Cancer 1Mouth Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Laryngeal Neoplasms 1Gestational Trophoblastic Disease 1Esophageal Squamour Cell Cancer 1Endometrioid Endometrial Cancer 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1Advanced Primary Liver Cancer 1

Interventions

Cisplatin 26Paclitaxel 21pembrolizumab 15Radiotherapy 13Carboplatin 13tislelizumab 12Fluorouracil 12Drug Therapy 11Irinotecan 9toripalimab 8Esophagectomy 8Oxaliplatin 6Nivolumab 6Capecitabine 6Neoadjuvant Therapy 5Leucovorin 5Docetaxel 5lenvatinib 4camrelizumab 4Taxes 4Radiation 4Levoleucovorin 4Immune Checkpoint Inhibitors 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4spartalizumab 3sintilimab 3Itraconazole 3Injections 3nimotuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × camrelizumab × 1 year × Clear all
NCT06654297 2026-04-02

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas

West China Hospital

Phase 1 Active not recruiting
6 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07505186 2026-04-01

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
45 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07312578 2025-12-31

Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell Carcinoma

Peking University

Phase 2 Enrolling by invitation
48 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07067450 2025-07-16

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

Sichuan University

Phase NA Not yet recruiting
98 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡